ERBB2 and cancer: Recently, the preliminary result from DAISY trial showed that patients with HER2 ultra-low expression (BCs with ≤10% of infiltrating cancer cells showing incomplete and faint/weak membrane staining) still showed an ORR of 30.6% [11].